ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,802.82
      -0.67%
      US Tech 100
      20,333.60
      -1.10%
      Dow Jones
      41,603.07
      -0.61%
      Brent Oil
      64.525
      0.00%
      Bitcoin
      107,974.25
      0.16%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Arbutus Biopharma Corporation (ABUS)

      7. Arbutus Biopharma Corporation (ABUS) News

      ABUS

      Arbutus Biopharma (ABUS)

      Arbutus Biopharma Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ABUS
      DateTimeSourceHeadlineSymbolCompany
      05/14/20255:21PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABUSArbutus Biopharma Corporation
      05/14/20257:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
      05/14/20257:30AMGlobeNewswire Inc.Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
      05/07/20256:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
      05/07/20252:01AMGlobeNewswire Inc.Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025NASDAQ:ABUSArbutus Biopharma Corporation
      04/23/20256:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
      04/23/20252:01AMGlobeNewswire Inc.Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025NASDAQ:ABUSArbutus Biopharma Corporation
      04/21/20252:11PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      04/15/20254:27PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      04/04/20254:06PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ABUSArbutus Biopharma Corporation
      04/04/20254:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ABUSArbutus Biopharma Corporation
      04/03/20254:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
      03/31/20254:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/31/20254:21PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/31/20259:42AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/27/20257:31AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ABUSArbutus Biopharma Corporation
      03/27/20257:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
      03/27/20257:30AMGlobeNewswire Inc.Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
      03/24/20259:19AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/20/20254:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/20/20254:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/19/20259:34AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/13/20253:55PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/07/20252:59PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/06/20254:13PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/06/20254:11PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/06/20254:08PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/06/20254:07PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
      03/03/20259:24AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
      03/03/20259:15AMGlobeNewswire Inc.Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaNASDAQ:ABUSArbutus Biopharma Corporation
       Showing the most relevant articles for your search:NASDAQ:ABUS